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Summary Study objective: This case-control study was conducted to test the
hypothesis that fasting homocysteine levels are higher in PPH patients than in healthy
controls. Design: Levels of plasma total homocysteine, serum folate, vitamin B-12,
and serum creatinine in 18 consecutive patients with PPH were compared with data
from 36 age- and sex-matched controls. Results: Eight of the 18 patients (44.4%) and
three of the 36 controls (8.3%) had elevated plasma total homocysteine (tHcy) levels
(X15 mmol/l, odds ratio 8.8; 95% CI: 2.0–39.6; P ¼ 0:005). There was an inverse
correlation between tHcy levels and creatinine clearance in patients with PPH
(P ¼ 0:036). Conclusion: PPH patients are significantly more likely to have
hyperhomocysteinemia, and higher mean plasma total homocysteine levels than in
controls. Plasma total homocysteine may be an important factor in the pathogenesis
of PPH.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Primary pulmonary hypertension (PPH) is a rare
disease of unknown etiology characterized by high
pulmonary artery pressures and pulmonary vascular
resistance.1 The pathogenesis of PPH is unknown,
but vasoconstriction, vascular remodeling, and
thrombosis of small pulmonary blood vessels are
thought to be contributory factors.2
The sulfur-containing amino acid homocysteine
and its oxidized derivatives, homocysteine, homo-
cysteine–cysteine-mixed disulfide and protein-
bound homocysteine, collectively known as plasma
total homocysteine (tHcy) are associated with some
types of endothelial and platelet dysfunction that
may be implicated in PPH. In healthy subjects,
mildly elevated tHcy levels impair vasodilation and
platelet function and facilitate coagulation and cell
adhesion.3 Thus, tHcy may facilitate platelet
deposition and clot formation and impair vasodila-
tion of the pulmonary arterioles, which could
contribute to the pathogenesis of PPH or worsen
existing cases. Hyperhomocysteinemia has been
implicated in the pathogenesis of atherosclerosis4–6
and of venous thromboembolism.7 One study that
concluded that PPH was not associated with high
tHcy levels8 was limited by the small number of
patients.
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In vitro studies suggest that homocysteine reacts
with nitric oxide (NO) produced by endothelial
cells.9 Homocysteine also impairs flow-mediated
vasodilation during transient hyperhomocysteine-
mia associated with methionine loading.10,11 We
recently found that levels of nitric oxide (NO) and
its biochemical reaction products are low in the
lungs of PPH patients.12 In addition, levels of
glutathione (an antioxidant) in the bronchoalveolar
fluid of these patients are high suggesting that PPH
is associated with a state of oxidative stress.12 For
these reasons, we hypothesized that PPH is
associated with elevated tHcy levels. We compared
PPH patients with healthy controls to determine
whether tHcy levels were higher in PPH patients,
and whether increased homocysteine levels were
associated with a higher risk of PPH.
Methods
Study design
In this case-control study, we compared 18 con-
secutive patients with PPH evaluated for lung
transplantation at the Cleveland Clinic Foundation
with 36 healthy controls. All of the patients and
controls were Caucasian. Controls were selected
from a pre-existing database of asymptomatic,
healthy individuals attending in the section of
Preventive Medicine at the same institution. The
control group was matched by age and sex with the
patient population. The study protocol was ap-
proved by the Institutional Review Board of The
Cleveland Clinic Foundation and informed consent
was obtained from all individuals participating in
the study.
Study protocol
Demographic data were collected and a history and
physical examination performed by a pulmonary
physician for all patients with PPH at the initial
assessment. PPH was diagnosed according to
standard diagnostic criteria used in the National
Registry for PPH.1 At the time of initial assessment,
fasting venous blood was drawn from both PPH and
control patients. All blood samples were analyzed
for tHcy, serum B-12, serum folate, complete blood
count (CBC), prothrombin time (PT), partial throm-
boplastin time (PTT), and serum creatinine. Control
patients with an abnormal CBC, PT, or PTT, and
subnormal folate and vitamin B-12 levels were
excluded from the study. Laboratory personnel
performing the assays were blinded to the patient’s
clinical and laboratory data.
Homocysteine and vitamin assays
Total plasma homocysteine was measured by the
method of Jacobsen et al.13 Blood samples were
collected in tubes containing ethylenediamine
tetracetic acid (EDTA) on ice and were centrifuged
within 1–2 h of collection in a refrigerated centri-
fuge. The plasma supernatant was stored at 701C
until the assays were performed. The assay
measured all forms of plasma homocysteine,
including reduced and oxidized forms (homocys-
teine, homocysteine–cysteine-mixed disulfide, and
homocysteine-mixed disulfide). Based upon prior
experiments, a homocysteine concentration equal
to or greater than 15 mmol/l was considered
abnormal.13,14 This level corresponded to the 90th
percentile in the screening database from which we
selected our control subjects.
Folic acid and B-12 concentrations in serum were
measured using a simultaneous radioligand-binding
assay (Becton Dickenson, Simultrac). Vitamin B-12
deficiency was defined as a plasma concentration
less than 200 pg/ml (normal range 200–600 pg/ml).
Folate deficiency was defined by a concentration
less than 3 ng/ml (normal range 3–16 ng/ml). Serum
creatinine was measured and the creatinine clear-
ance was estimated by a previously described
formula.15
Statistical analysis
Normally distributed continuous data were sum-
marized with means, standard deviations, and
ranges, and skewed data with medians. Nominal
data were summarized with frequency and per-
cent. The association between predictor variables
and the presence of PPH was assessed with logistic
regression, with odds ratios (odds of having PPH in
those with a risk factor versus those without) and
their 95% confidence intervals. The PPH and non-
PPH groups were also compared on continuous
variables with two-sided t-tests or Wilcoxon rank
sum tests and on nominal variables with likelihood
ratio chi-square or Fisher’s exact tests. Correlations
among continuous variables were assessed with
Spearman or Pearson correlation analysis, as
appropriate. A significance level of alpha¼ 0.05
was used for all hypotheses. All statistical analyses
were performed using SAS statistical software
(version 6.12, Cary, NC, USA).
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Results
There were six males and 12 females with PPH with
a median age of 43 years (range: 13–73 years). The
median duration of PPH in the patient population
was 9 months (range: 3–81 months). Other char-
acteristics are shown in Table 1.
There were 36 subjects in the control group.
Controls were matched for sex and age, and they
had demographic characteristics similar to the PPH
patients. The only variable that differed slightly
(although non-significantly) between the cases and
controls was the frequency of cigarette smoking; 2/
18 patients (11.1%) of the PPH group were smokers
versus 2/36 (5.6%) in the control group (P ¼ 0:47;
odds ratio 2.1, 95% CI: 0.27–16.5).
Table 2 shows that abnormally elevated tHcy
levels were much more frequent among PPH
patients than among controls, even after adjusting
for serum creatinine level (P ¼ 0:013). The mean
tHcy levels were higher in PPH patients. Among
patients with PPH, no significant correlation was
found between tHcy and mean pulmonary artery
pressure (PAP) (Spearman correlation 0.064,
P ¼ 0:80). All PPH patients had normal levels of
serum vitamin B-12 and folate.
Serum creatinine was correlated with tHcy for
the combined group of PPH patients and controls
(Spearman correlation 0.35, P ¼ 0:01). For PPH
patients, the Spearman correlation was 0.45
(P ¼ 0:062). For control patients, the Spearman
correlation was 0.32 (P ¼ 0:06). The mean creati-
nine clearance in patients with PPH was
124749ml/min. There was an inverse correlation
between tHcy levels and the creatinine clearance
in patients with PPH (Pearson correlation was
–0.50; 95% CI: 0.04, 0.78; P ¼ 0:036).
Discussion
In this study, a high proportion of patients with PPH
(44.4%) had elevated levels of tHcy. Mean tHcy
levels were also higher in PPH patients than in
control subjects. In addition tHcy levels415mmol/l
was still predictive of PPH after adjusting for
serum creatinine. However, there was an inverse
correlation between the creatinine clearance and
the tHcy levels in patients with PPH.
The patients with PPH had normal level of
creatinine clearance (124749ml/min); however,
we found an inverse correlation between the
creatinine clearance and the tHcy levels. High
plasma value of tHcy is a common feature in
patients with advanced renal failure and is an
independent risk factor for atherothrombotic dis-
ease in patients with renal dysfunction.16 The
mechanism(s) that may explain the association
between the degree of creatinine clearance and
the tHcy levels is(are) unknown.
Serum vitamin B-12 and folate levels did not
differ between patients with PPH and controls. We
did not examine the effect of folate, vitamin B-12,
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Table 1 Characteristics of patients with PPH
Demographic variable Value (N ¼ 18)
Age in years, median (range) 43 (13–73)a
Male gender 6 (33.3%)
Duration of PPH in months,
median (range)
9 (3–81)
PAP (mmHg), median
(range)
52 (30–89)
Cardiac index (l/min/m2),
median (range)
2.08 (1.2–3.7)
Patients on epoprostenol 6 (33.3%)
Patients on Caþ þ channel
blockers
5 (27.8%)
Patients on coumadin 13 (72.2%)
PPH¼primary pulmonary hypertension, PAP¼pulmonary
artery pressure, Caþ þ ¼ calcium.
aFrequency unless stated.
Table 2 Comparison of tHcy, folate, vitamin B-12 and creatinine in PPH patients and controls
Variable PPH (N ¼ 18) Controls (N ¼ 36) Odds ratio (95% CI) P value
THcy level (mean7SD) (mmol/l) 14.777.2 10.275.1 1.14 (1.02–1.3) 0.027*
Patients with tHcyX15 mmol/l (%) 8 (44.4%) 3 (8.3%) 8.8 (2.0–39.6) 0.005*
Serum folate (mean7SD) (ng/ml) 8.673.6 7.974.5 1.04 (0.9–1.9) 0.61
Serum B-12 (mean7SD) (pg/ml) 441.57155.9 387.27157.6 1.02 (0.98–1.06) 0.24
Serum creatinine (mean7SD) (mg/dl) 1.070.2 0.970.2 1.3 (0.99–1.8) 0.06
PPH¼primary pulmonary hypertension. Odds ratio shows relative odds of having PPH with 1-unit increase (in continuous
variables) or with positive value (for nominal variable). P values from logistic regression, * statistically significant if Po0:05:
THcy¼ total homocysteine.
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or vitamin B-6 supplementation in patients with
hyperhomocysteinemia. The effect of folate, B-12,
and B-6 supplementation in patients with hyperho-
mocysteinemia and PPH needs to be studied
further.
We postulate that irrespective of the reasons for
the high levels of tHcy, hyperhomocysteinemia may
have deleterious effect in patients with PPH. What
may be the role of homocysteine in PPH? Homo-
cysteine may exert its effect on the pulmonary
vasculature by promoting vasoconstriction, pro-
moting endothelial dysfunction, and enhancing in
situ thrombosis by complex mechanisms. Homo-
cysteine is readily oxidized in plasma to homocys-
tine, homocysteine-mixed disulfides, and
homocysteine thiolactone. Generation of super-
oxide and hydrogen peroxide during oxidation may
enhance endothelial toxicity and lipid peroxidation
in the pulmonary vasculature.17,18 Furthermore,
hyperhomocysteinemia is prothrombotic because it
increases levels of factors XII and V, decreases
activation of protein C, inhibits thrombomodulin,
induces expression of tissue factor, suppresses
heparin sulfate, and reduces binding of tissue
plasminogen activator to endothelial receptors.19
Nitric oxide produced by endothelial cells may
detoxify homocysteine by forming S-nitrosohomo-
cysteine, which can serve as a vasodilator and
platelet inhibitor.9 This protective action of nitric
oxide appears to be overwhelmed by chronic
hyperhomocysteinemia, which leads to unopposed
action of homocysteine on vascular endothelium
with resultant oxidative injury.17 In addition,
homocysteine inhibits glutathione peroxidase (en-
dothelial antioxidants), changing cellular redox
potential and causing endothelial injury.9 These
deleterious effects of homocysteine may play a
significant role in patients with PPH who already
have low levels of NO in the lungs and in a state of
oxidative stress12 further amplifying any endothe-
lial injury caused by homocysteine. Finally, hyper-
homocysteinemia may promote vascular smooth
muscle proliferation by inhibiting NO and
by increasing cyclin D1 and cyclin A mRNA
expression.20,21
Conclusion
Plasma total homocysteine levels are significantly
higher in patients with PPH compared with age- and
sex-matched controls. Mean serum folate, vitamin
B-12, and serum creatinine do not appear to differ
significantly between cases and controls. Based on
the results of this study, we postulate that
homocysteine may play an important role in the
pathogenesis of PPH. Larger studies of patients
with PPH could clarify this issue and evaluate the
potential benefits of folic acid, vitamin B-12,
vitamin B-6, and antioxidant therapy in PPH.
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